Holen Sie sich die Stockscreener-App
2.065
1.89%
-0.055
Schlusskurs vom Vortag:
$2.12
Offen:
$2.12
24-Stunden-Volumen:
85,498
Relative Volume:
0.21
Marktkapitalisierung:
$131.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.92M
KGV:
-3.4251
EPS:
-0.6029
Netto-Cashflow:
$-27.39M
1W Leistung:
-0.48%
1M Leistung:
-2.35%
6M Leistung:
+23.08%
1J Leistung:
-11.49%
1-Tages-Spanne:
$2.05
$2.15
1-Wochen-Bereich:
$2.0403
$2.18
52-Wochen-Spanne:
$0.41
$3.43
Tuhura Biosciences Inc Stock (HURA) Company Profile
Firmenname
Tuhura Biosciences Inc
Sektor
Branche
Telefon
813-875-6600
Adresse
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.07 | 135.10M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-03-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-11-05 | Eingeleitet | Maxim Group | Buy |
Tuhura Biosciences Inc Aktie (HURA) Neueste Nachrichten
TuHURA Biosciences Inc (NASDAQ: HURA) Share Price, HURA Stock News, HURA Share Price & Updates - Kalkine
A cancer drug company CEO will speak in New York on Sept. 14 - Stock Titan
TuHURA Biosciences to Present at Investment Conference - Intellectia AI
TuHURA Biosciences draws additional funds from credit facility - TipRanks
TuHURA Biosciences, Inc.Common Stock (HURA) Stock Price, News, Quote & History - FinancialContent
HURA: Milestone Progression Over Next 12 Months - Yahoo Finance
TuHURA Biosciences | 8-K: Current report - Moomoo
H.C. Wainwright Maintains TuHURA Biosciences(HURA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Breakout Confirmation - dars.gov.et
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com Canada
HURA: All proposals passed, including director elections and share issuance, with no stockholder questions - TradingView
HURA: All proposals, including director elections and share issuance, were approved without dissent - TradingView
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
HURA Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Jump 7.4%Low Estimate Range - vinanet.vn
TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA - Moomoo
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances - TipRanks
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - MarketBeat
TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY - scanx.trade
TuHURA Secures $50M Credit Facility Extending Cash Runway into 2028 - Minichart
Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update - TradingView
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) deepens R&D spend and adds $50M credit facility - Stock Titan
TuHURA Reports $1.0 Million Cash and Advances TBS-2025 AML Program - Quiver Quantitative
TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway - TradingView
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences (HURA) Earnings Date and Reports 2026 - marketbeat.com
TuHURA at canaccord growth conference: late-stage push gains traction By Investing.com - Investing.com Nigeria
TuHURA at canaccord growth conference: late-stage push gains traction - Investing.com
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
TuHURA Biosciences (HURA) Slips 1.38% as Biotech Stock Holds Above Key $2.03 SupportGap Up Stocks - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Oncology Pipeline Drives CostsNew Analyst Coverage - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss With No Revenue and Stock Advance Defies ResultsSurprise Factor Analysis - vinanet.vn
TuHURA Biosciences (HURA) Slips 3.62% as Shares Test Support Near $2.02Swing Entry Signals - dars.gov.et
TuHURA Biosciences Inc (HURA) Cash Flow - TradingKey
TuHURA Biosciences Inc (HURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TuHURA Biosciences Inc (HURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TuHURA Biosciences Inc (HURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HURA|TuHURA Biosciences Inc|Price:2.110|Chg%:-0.040 - TradingKey
TradingKey - TradingKey
HURA|TuHURA Biosciences Inc|Price:2.210|Chg%:+0.100 - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HURA Stock Price, Quote & Chart - ChartMill
TuHURA Biosciences to Present at Canaccord Genuity Conference - Intellectia AI
TuHURA CEO to present at Canaccord Genuity Grow... - Pluang
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference - PR Newswire
TuHURA Biosciences (HURA) Proxy filing Summary - Quartr
Finanzdaten der Tuhura Biosciences Inc-Aktie (HURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):